Key result
The G20210A mutation in the prothrombin gene did not significantly increase the risk of early recurrent venous thromboembolism compared to non-carriers (RR 0.6, 95% CI 0.2-1.8).
Why the study?
Does the G20210A transition in the prothrombin gene increase the risk of recurrent venous thromboembolism in patients with a history of VTE after discontinuation of oral anticoagulants?
Cohort (n=492)
Yes
Does the G20210A transition in the prothrombin gene increase the risk of recurrent venous thromboembolism in patients with a history of VTE after discontinuation of oral anticoagulants?
Relative Risk: 0.6 (95% CI 0.2–1.8)
Absolute Event Rate: 8% vs 12.2%
p-value: p=0.3
The G20210A mutation does not increase the risk of early recurrent venous thromboembolism, suggesting long-term secondary thromboprophylaxis is not justified for heterozygous carriers.
No takes yet. Share an insight, caveat, or question.
Recurrence risk not elevated in G20210A carriers; leaves open whether genotyping informs secondary prophylaxis duration.
Minar et al. (1999) conducted a cohort in Venous thromboembolism (n=492). G20210A mutation in the prothrombin gene vs. Patients without the G20210A mutation was evaluated on Recurrent venous thromboembolism (RR 0.6, 95% CI 0.2-1.8, p=0.3). The G20210A mutation in the prothrombin gene did not significantly increase the risk of early recurrent venous thromboembolism compared to non-carriers (RR 0.6, 95% CI 0.2-1.8).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: